Key result
Intranasal bumetanide achieves decongestion in a patient with oral diuretic resistance, bridging to successful TMVR.
Why the study?
Patients with advanced valvular disease frequently experience oral diuretic resistance.
Case Report (n=1)
Intranasal bumetanide may serve as an effective nonoral diuretic bridge to advanced structural interventions in patients with oral diuretic resistance, allowing for home administration and avoidance of hospitalizations.
Answers are grounded in this paper and cite their sources.
May bridge decongestion in select diuretic-resistant valvular cases; leaves open need for prospective validation.
Patients with advanced valvular disease frequently experience oral diuretic resistance. We describe the use of intranasal bumetanide, a nonoral diuretic, in a 76-year-old woman with severe mitral regurgitation who had recurrent volume overload and oral diuretic resistance. Decongestion following intranasal bumetanide ultimately allowed for advanced evaluation and successful transcatheter mitral valve replacement. This case demonstrates that nonoral diuretic therapy may serve as an effective bridge to advanced structural interventions, allowing for home administration and avoidance of hospitalizations. Nonoral diuretics can be an alternative to preadmission and in-hospital optimization before minimally invasive valvular procedures.
No takes yet. Share an insight, caveat, or question.
Rushakoff et al. (2026) conducted a case report in Diuretic-Resistant Heart Failure and severe mitral regurgitation (n=1). Intranasal bumetanide was evaluated on Decongestion allowing for advanced evaluation and successful transcatheter mitral valve replacement. Intranasal bumetanide successfully achieved decongestion in a patient with oral diuretic resistance, serving as an effective bridge to transcatheter mitral valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: